Retrieve Medical (RMHI) 10-K 12 Jan 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Mar. 31, 2013
Document and Entity Information:
Entity Registrant Name	Peak Pharmaceuticals, Inc.
Document Type	10-K
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Entity Central Index Key	1452804
Current Fiscal Year End Date	-21
Entity Common Stock, Shares Outstanding		78,363,567
Entity Public Float			$54,936,072
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Sep. 30, 2013
Current Assets
Cash	$451,431	$4,906
Prepaid Expenses	6,838
Total Current Assets	458,269	4,906
Intangible Asset, Net of Amortization	30,139
Deposit	2,500
Total Assets	490,908	4,906
Current Liabilities
Accounts Payable And Accrued Liabilities	43,534	9,636
Account Payable - Related Parties	10,893
Due to Related Party		34,510
Total Current Liabilities	54,427	44,146
Total Liabilities	54,427	44,146
Commitments and Contingencies
Stockholders' Equity
Common stock	7,816	33,075
Additional Paid-in Capital	4,287,720	27,925
Accumulated Deficit	-3,859,055	-100,240
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	325,000,000	325,000,000
Common stock, shares issued	78,163,562	330,750,000
Common stock, shares outstanding	78,163,562	330,750,000
Total Stockholders' Equity (Deficit)	436,481	-39,240
Total Liabilities and Stockholders' Equity (Deficit)	$490,908	$4,906

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Expenses
Cost Associated with Exploring Business Opportunity	$412,114
General and Administrative	2,674,723	12,341
Total Operating Expenses	2,674,723	12,341
Loss From Operations	-3,086,837	-12,341
Other Income and (Expense)
Gain on Extinguishment of Debt	24,650
Interest Expense	-696,628
Total Other Income and (Expense)	-671,978
Net Loss	($3,758,815)	($12,341)
Basic and Diluted (Loss) per Common Share	($0.05)	$0
Weighted Average Number of Common Shares Outstanding	75,229,245	330,750,000

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid in Capital	Deficit Accumulated	Total Stockholders' Equity (Deficit)
Stockholder Equity at Sep. 30, 2012		$33,075	$27,925	($87,898)	($26,898)
Shares Issued at Sep. 30, 2012		330,750,000
Net Loss	-12,341			-12,342	-12,342
Stockholder Equity at Sep. 30, 2013	-39,240	33,075	27,925	-100,240	-39,240
Shares Issued at Sep. 30, 2013		330,750,000
Shares Issued for Cash		3,782	1,036,218		1,040,000
Shares Issued for Cash (Shares)		37,825,000
Shares Cancelled	30,000	-30,000	30,000
Shares Cancelled (Shares)		-300,000,000
Shares Repurchased		-3,325	-121,675		-125,000
Shares Repurchased (Shares)		-33,250,000
Shares Issued for Services to Employees and Directors		3,758	246,801		250,559
Shares Issued for Services to Employees and Directors (Shares)		37,583,998
Shares Issued for Services to Non-Employees		53	537,147		537,200
Shares Issued for Services to Non-Employees (Shares)		526,666
Shares Issued for Debt Conversion		473	659,167		659,640
Shares Issued for Debt Conversion (shares)		4,727,898
Equity Based Compensation	1,222,357		1,222,357		1,222,357
Effect of Beneficial Conversion Feature	649,780		649,780		649,780
Net Loss	-3,758,815			-3,758,815	-3,758,815
Stockholder Equity at Sep. 30, 2014	$436,481	$7,816	$7,287,720	($3,859,055)	$436,481
Shares Issued at Sep. 30, 2014		78,163,562

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows
Net Loss	($3,758,815)	($12,341)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Amortization of Website	4,861
Effect of Beneficial Conversion Feature	649,780
Shares Issued for Services to Employees and Non-Employees	787,759
Equity Based Compensation	1,222,357
Gain on Conversion of Debt	-24,650
Debt Issued for Services	102,932
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	-6,838	3,268
(Increase) Decrease in Deposits	-2,500
(Increase) Decrease in Accounts Payable and Accrued Liabilities	80,746	-6,494
(Increase) Decrease in Accounts Payable - Related Parties	10,893
Net Cash Used in Operating Activities	-933,475	-15,567
Cash Flows From Investing Activities:
Website Development Cost	-35,000
Net Cash Used in Investing Activities	-35,000
Cash Flows From Financing Activities:
Sale of Stock	1,040,000
Shares Redeemed for Cash	-125,000
Proceeds from Note Payable	500,000
Advances from Related Party		15,510
Net Cash Provided by Financing Activities	1,415,000	15,510
Increase (Decrease) in Cash	446,525	-57
Initial Cash	4,906	4,963
Final Cash	451,431	4,906
Non-cash Financing Activities:
Common Shares for Settlement of Debt	9,860
Conversion of Debt into Common Shares	649,780
Shares Cancelled	$30,000

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Notes
Note 1 - Summary of Significant Accounting Policies	Note 1 – Summary of Significant Accounting Policies
	Peak Pharmaceuticals, Inc., (“our,” “we,” “us,” and the “Company”) was incorporated in Nevada on December 18, 2007 as Surf A Movie Solutions Inc., which was previously engaged in the development, sales and marketing of online video stores. We decided to change our business objective and in connection therewith we first changed our name to Frac Water Systems, Inc.
	On October 10, 2013, we entered into a Joint Venture Agreement (the “JV Agreement”) with Produced Water Solutions, Inc., a Colorado corporation (“PWS”) in the business of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities (the “Business”). The JV Agreement was intended to enable us to engage in and commence activities involving the Business. In furtherance thereof, pursuant to the JV Agreement, PWS provided us with three prospective Business projects (the “Projects”) and agreed to provide us with consulting services with respect to all aspects of the Projects and certain additional Business projects that we may subsequently determine to pursue (the “Additional Projects”). We agreed to accept at least one of the Projects (the “Guaranteed Project”) and were granted a right of first refusal until December 31, 2013 with respect to the two other Projects.
	In consideration for consulting services to be rendered, we had agreed to pay PWS a Monthly Project Cash Fee, a Cash Bonus Payment, 375,000 FWSI Stock Options and Net Income Payments.
	On December 31, 2013, we determined not to move forward with our proposed business of providing solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and production activities. On December 31, 2013 we notified PWS of our determination to terminate the JV Agreement effective January 30, 2014 (the “Termination Date”). As of the Termination Date, we have no further obligation to make monthly project cash fee payments or bonus payments to PWS which were previously required under the JV Agreement. The options previously granted remain outstanding.
	As more fully described in Note 6, on March 11, 2014 our board of directors authorized a 1.5 for 1 forward split of our common stock in the form of a stock dividend.  Accordingly, all references to numbers of common shares and per-share data in the accompanying financial statements have been adjusted to reflect the Stock Split on a retroactive basis.  The split did not affect the authorized capital.  This restatement gives the appearance that we issued more shares than were authorized on September 30, 2013. When in fact we were below our authorized capital at that time.
	On March 14, 2014, we changed our name to Cannabis Technology Corp. The name change was made in connection with our entry into the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases.  On December 23, 2014, we changed our name again to Peak Pharmaceuticals, Inc.  This name change was made to make our name more consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets.
	Financial statements prepared in conformity with GAAP contemplate a company’s continuation as a going concern. We have incurred net losses since inception. In addition, we have an accumulated deficit of $3,859,056  as of September 30, 2014. This condition raises substantial doubt as to our ability to continue as a going concern. In response to these conditions, we may raise additional capital through the sale of equity securities, through an offering of debt securities or through borrowings from financial institutions or individuals. These financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
	Basis of Consolidation
	The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak Biopharma Inc. All inter-company balances and transactions among the companies have been eliminated upon consolidation.
	Development Stage Company
	The company has limited operations and is considered to be in the development stage. In the year ended September 30, 2014, the Company has elected to early adopt Financial Accounting Standards Board ("F ASB") Accounting Standards Update ("ASU") No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage.
	Use of Estimates
	The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues and expenses during the years reported. Actual results may differ from these estimates.
	Fair Value Measurements:
	ASC Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange.
	Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs.
	Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights.
	Cash and cash equivalents
	Our financial instruments consist of cash and cash equivalents, prepaid expenses, payables, and accrual. The carrying values of these instruments approximate fair value because of the short term maturities of these instruments.
	Intangible asset
	Intangible asset is our website and is being amortized over the expected useful lives which we estimate to be three.  Amortization expense charges to income for the year ended September 30, 2014 was $4,861.  There was no amortization expense for the year ended September 30, 2013.
	Long-lived assets
	On a periodic basis, management assesses whether there are any indicators that the value of our long-lived assets may be impaired. An asset’s value may be impaired only if management’s estimate of the aggregate future cash flows, on an undiscounted basis, to be generated by the asset are less than the carrying value of the asset.
	Our only longed lived asset is our website.  If impairment has occurred, the loss is measured as the excess of the carrying amount of the asset over its fair value.  Our estimates of aggregate future cash flows expected to be generated by our long-lived asset are based on a number of assumptions that are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in their impairment analyses may not be achieved. As of September 30, 2014, there was no asset impairment.
	Expenses associated with exploring business opportunities
	We were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of PWS Notes and other payments under the JV Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the assumption of debt related to the JV Agreement (See Note 4) and $2,413 which is the fair value of options granted to PWS (See Note 7).
	Research and Development
	Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $30,000 in research and development expenses for the year ended September 30, 2014.  There were no research and development expenses in 2013.
	Income Taxes
	The provision for income taxes is determined in accordance with the provisions of ASC Topic 740, Accounting for Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements, uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
	For the years ended September 30, 2014 and 2013 we did not have any interest and penalties or any significant unrecognized uncertain tax positions. As of September 30, 2014 and 2013, we did not have any significant unrecognized uncertain tax positions.
	Loss per Share
	We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period, and diluted earnings per share is computed by including Common Stock equivalents outstanding for the period in the denominator. We have not issued any potentially dilutive common shares. At September 30, 2014 and 2013 any equivalents would have been anti-dilutive as we had losses for the periods then ended.
	Recent Pronouncements
	From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.  ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly.

Note_2_Intangibles

Note 2 - Intangibles	12 Months Ended
	Sep. 30, 2014
Notes
Note 2 - Intangibles	Note 2 - Intangibles
	Intangibles consist of Website, $35,000, less accumulated amortization of $4,861.  The website is being amortized over three years.
	Estimated future amortization expense related to intangible property as of September 30, 2014 is as follows:
	Years ending September 30,	Total Amortization
	2015	$	11,667
	2016		11,667
	2017		6,805
		$	30,139

Note_3_Related_Party_Transacti

Note 3 - Related Party Transactions	12 Months Ended
	Sep. 30, 2014
Notes
Note 3 - Related Party Transactions	Note 3 –Related Party Transactions
	Accounts payable – related party
	Accounts payable – related parties are the amounts payable to an officer and a director of the Company for reimbursement of expenses they incurred on behalf of the Company.
	Due to Related Party
	Parties, which can be corporations or individuals, are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.
	We issued 1,479,000 shares of common stock to a former officer of the Company, to settle $34,510 of debt. The fair value of the shares issued is $9,860 or $0.0067 per share. We recognized a gain on the settlement of debt of $24,650 for the difference of the fair value of the shares and the amount payable to the former officer. As of September 30, 2014, we are no longer indebted to the former officer.
	Agreements
	On June 26, 2014, we entered into a Services Agreement (the “Services Agreement”) with Caerus Discovery, LLC, (“Caerus”) a biotech company, whereby Caerus will be providing us with research services for the purpose of executing specific, specialized cell-based assays and animal studies intended to support product development and design of our proposed anti-inflammatory and autoimmune disease prevention and alleviation products. In connection therewith, we may be supplying Caerus with confidential materials and information including, but not limited to, intellectual property, know-how, data, test results, written materials and similar information (collectively, the “Materials and Information”). The research services will be conducted within Caerus’s laboratories by Caerus’s trained personnel. All patents, patent applications, trademarks, trade names, inventions, copyrights, know-how, and trade secrets (collectively, the “IP Rights”) related to the Materials and Information and arising thereunder will be owned by us. Similarly, if Caerus develops or discovers any development, invention, improvement, modification, product, use, method, technique, conception, know-how, technical data, specification, information, or result relating to any Materials and Information, including new substances (collectively, the “Developments”), Caerus will execute any assignments necessary to transfer title thereto to us. We will have sole responsibility, at our expense, for the preparation, filing, prosecution and maintenance of patent applications and rights related to Developments and results of the services provided to us by Caerus. Pursuant to the Services Agreement we have granted to Caerus a non-exclusive, royalty free license, without the right to grant sublicenses, in any IP Rights and Developments for the limited purpose of conducting the services under the Services Agreement. Our Materials and Information is being protected under the confidentiality provisions of the Services Agreement. Caerus will invoice us for rendered services on a project by project basis with payment due within 30 days thereof. The scope and approximate cost of each project will be defined and agreed upon prior to the start of each project. The Services Agreement will terminate upon the earlier of (i) completion of all requested services; (ii) 30 days after we supply Caerus with written notices of termination; or (iii) June 30, 2015.  To date, we have not used any services from Caerus, nor paid any fees to Caerus.
	One of our directors, is the Chief Executive Officer, President, and Principal Equity Holder of Caerus. Our President, Chief Executive Officer and a director previously served as Caerus’ Vice President of Research and Development.

Note_4_ShortTerm_Convertible_N

Note 4 - Short-Term Convertible Notes Payable	12 Months Ended
	Sep. 30, 2014
Notes
Note 4 - Short-Term Convertible Notes Payable	Note 4 – Short-Term Convertible Notes Payable
	On October 10, 2013, we entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with PWS and Montrose Capital Limited (“Montrose”) related to the termination of a June 13, 2013 Term Sheet (the “Term Sheet”) among us, PWS and Montrose. The Term Sheet contemplated a $250,000 bridge financing for PWS involving the sale of $250,000 in principal amount of secured convertible promissory notes of PWS (the “PWS Notes”) and a subsequent reverse triangular merger (the “Merger”) among us, PWS and the shareholders of PWS in which PWS would become a wholly-owned subsidiary of ours. On July 1, 2013 the $250,000, bridge financing was completed and the PWS Notes were issued. The Notes were subject to mandatory conversion at the effective time of the Merger into securities of ours. The parties to the Settlement Agreement subsequently determined not to proceed with the Merger, choosing instead to have us engage directly in the Business pursuant to a Joint Venture Agreement. The JV Agreement discussed in Note 1 was the result thereof.
	As a result we became liable for $602,932 in short term notes, which include the original principal of $500,000 and accrued interest of $102,932.  On June 30, 2014 the Holders agreed to convert the Notes into common stock of the Company at a conversion price of $0.20 per share for the outstanding principal of $602,932 and accrued interest of $46,848.  We issued 3,248,898 share of our common stock to the Holders.  In accordance with guidance in Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) Topic 470, Debt, we recognized a beneficial conversion feature to the debt and wrote-off the discount at the date of conversion.  The discount of $649,780 was recorded as interest expense.

Note_5_Commitments_and_Conting

Note 5 - Commitments and Contingencies	12 Months Ended
	Sep. 30, 2014
Notes
Note 5 - Commitments and Contingencies	Note 5 – Commitments and Contingencies
	Canna-Pet License Agreement
	On July 29, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with Canna-Pet, LLC, (“Licensor”) a Washington limited liability corporation, which owns the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”), used by Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp which are intended exclusively for consumption by pets. Pursuant to the License Agreement, Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gives us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provides us with an immediate revenue source and access to Licensor’s customer base. During the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor.
	In consideration of the grant of the license, we have agreed to pay Licensor license fees in the form of royalty payments calculated on the basis of gross proceeds received by us from sales of products manufactured, marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor.
	The royalty will be calculated and paid by us on a quarterly basis using calendar quarters ending March 31, June 30, September 30, and December 31 each year and will be equal to fifteen percent (15%) of the first $1,000,000 of gross proceeds received by us during the quarter and ten percent (10%) on gross proceeds in excess of $1,000,000 received by us during the quarter. On or before the date, which is 45 days following the end of each calendar quarter, we will calculate the amount of the royalty due to Licensor for that quarter and will make payment in full of such amount to Licensor. For purposes of calculating the amount of royalty due for each quarter, “gross proceeds” will not include amounts received by us as payments for any and all taxes, duties, governmental charges, sales expenses, freight or shipping charges, and the like.
	Commencing in 2015, we have agreed to pay Licensor guaranteed minimum royalty amounts based upon the gross proceeds received by us from the sale of products (the “License Based Products”) utilizing the Licensed Intellectual Property or subsequently developed jointly owned intellectual property. The guaranteed minimum royalty payments are as follows:
	Time Period		Minimum Annual License Fee
	January 1, 2015 through December 31, 2015			-1
	January 1, 2016 through December 31, 2016			-2
	January 1, 2017 through December 31, 2017			-2
	January 1, 2018 through December 31, 2018			-2
	January 1, 2019 through December 31, 2019			-2
	January 1, 2020 through December 31, 2020, and all succeeding years			-3
	(1)	Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000.
	(2)	Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31.
	(3)	The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019.
	All royalty payments made by us during any calendar year will be credited against the minimum annual royalty amounts due and payable by us for such year. In the event that the aggregate amount of royalties payable by us for any calendar year are not sufficient to satisfy our minimum annual royalty payment obligation for that year, we will be obligated to pay the unpaid balance of the minimum royalty amount to Licensor on or before February 28 of the following year.
	Licensor has agreed to defend, at its own expense, any action against Licensor or us based on a claim that the Licensed Intellectual Property infringes a US or foreign patent, a US or foreign copyright or involves misappropriation of a trade secret.
	The License Agreement may be terminated
	·         By mutual consent of us and Licensor;
	·         By us, upon 90 days prior written notice to lender;
	·         By Licensor, upon written notice to us if any of the following events occur:
	(i)                 our failure to pay Licensor royalty payments within fifteen (15) days after we receive written notice that payment is overdue, provided that there is no good faith dispute over the fees or charges; or
	(ii)               our failure to pay the minimum annual royalty payment for any year within fifteen (15) days after we receive written notice that payment is overdue, provided that there is no good faith dispute over the total amount due; or
	(iii)             any breach by us of any material term or obligation of the License Agreement if not remedied within thirty (30) days after we receive written notice of such breach, provided that this time will be extended to the extent we have made a good faith effort to resolve any such breach; or
	(iv)             we are acquired by another entity and our successor is unwilling to assume our obligations under the License Agreement, or refuses to enter into an Assumption of Obligations Agreement; or
	(v)               we cease doing business as a going concern. Our right to use the Licensed Intellectual Property ceases upon termination of the License Agreement.
	In the event intellectual property is developed jointly by us and Licensor (including any development by us using the Licensed Intellectual Property) during the performance of the License Agreement, the ownership of such intellectual property will be determined according to principles of United States patent law. In such event, the parties have agreed to negotiate in good faith towards an intellectual property management agreement to define their respective rights and obligations with respect to legal protection, payment of expenses, licensing and infringement of any intellectual property which is jointly owned by the parties. Any party that does not bear its proportionate share of expenses in securing and maintaining patent protection on jointly owned intellectual property in any particular country or countries will be required to surrender its joint ownership under any resulting patents in such country or countries.
	Non-cancelable Operating Lease
	We lease office space under non-cancelable operating lease, which expires August 31, 2015.  There are no automatic extension periods in the lease.
	The aggregate minimum requirements under non-cancelable leases as of September 30, 2014 are as follows:
	Years ending September 30,
	2015		$	13,750
	Rent expense was $4,667 for the year ended September 30, 2014.  There was no rent expense incurred for the year ended September 30, 2013.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	12 Months Ended
	Sep. 30, 2014
Notes
Note 6 - Stockholders' Equity	Note 6 – Stockholders’ Equity
	On March 11, 2014 our board of directors authorized a 1.5 for 1 forward split of our common stock in the form of a stock dividend (the “Stock Split”). In connection therewith, Company shareholders of record as of the close of business on March 27, 2014, the record date, received an additional .5 shares of our common stock for each share of our common stock held by them on the record date. Accordingly, all references to numbers of common shares and per-share data in the accompanying financial statements have been adjusted to reflect the Stock Split on a retroactive basis.
	On October 10, 2013, we issued 30,000,000 shares at $0.0067 per share, to a then officer of the Company, for total proceeds of $200,000. On March 11, 2014 we repurchased 29,500,000 of these shares for an aggregate of $100,000. Prior to the repurchase, the officer and director resigned.
	In addition, on October 10, 2013, a former officer and director and a former director of ours delivered to us an aggregate of 300,000,000 shares of common stock of ours for cancellation. The cancellation of these shares was made in conjunction with the resignation of the positions they held.
	On October 15, 2013, we issued 3,750,000 shares at $0.0067 per share, to two directors of the Company for total proceeds of $25,000. On January 30, 2014 in connection with the termination of the JV Agreement and the resignation of the two directors, we repurchased these 3,750,000 shares for $25,000, the amount paid.
	On November 15, 2013, we issued 1,479,000 shares of our common stock in settlement for $34,510 due to a former related party. (Note 3)
	On March 11, 2014, we issued 37,584,000 shares to 3 individuals and their assignees for services rendered. The shares were valued at $0.0067 per share, the amount paid by the Company to repurchase shares on the same date. The total amount, $250,599 was recognized as equity based compensation.
	During the period from April through September, we sold a total of 4,075,000 shares of our common stock at a price of $0.20 per share for total proceeds of $815,000. There was no cost attributed to these sales.
	On May 15, 2014 we entered into an agreement for investor relation services.  The agreement provided for the issuance of 466,666 shares of our common stock.  Pursuant to the agreement the stock was earned in June and July 2014.  The stock was valued at $476,000, $1.02 per share, the trading value at the date earned and was charged to expense.
	On June 25, 2014 we entered into an agreement for public and investor relations services. The agreement is for a period of 90 days. The agreement requires the fee to be settled by our issuance of 60,000 restricted shares of our common stock. The shares were issued on July 14, 2014 and are valued at $61,200, $1.02 per share, the trading value, and has been charged to expense.
	On June 30, 2014 we issued 3,248,898 shares of our common stock in connection with the conversion of debt (see Note 4).

Note_7_Options

Note 7 - Options	12 Months Ended
	Sep. 30, 2014
Notes
Note 7 - Options	Note 7 – Options
	In connection with the JV Agreement described in Note 1, we issued options to purchase 375,000 shares of our common stock. The options have a term of 10 years, are exercisable at $0.0067 per share and vest twelve months from the date of issuance, October 10, 2013.
	The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $2,413. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model:
	Expected life (in years)		10
	Volatility (based on a comparable companies)		130	%
	Risk Free interest rate		2.71	%
	Dividend yield (on common stock)		-
	During October 2013 through December 31, 2013 we issued options to purchase 1,125,000 shares of our common stock (375,000 to each of our Chief Executive Officer and two Directors). The options had a term of 10 years, were exercisable at $0.0067 per share and vested one year from the date of issuance. In addition we issued options to purchase 262,500 shares of our common stock to our Chief Financial Officer. The options had a term of 10 years, were exercisable at $0.0067 per share and vested quarterly over the next year.
	The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $5,859. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model:
	Expected life (in years)		10
	Volatility (based on a comparable companies)		130	%
	Risk Free interest rate		2.71	%
	Dividend yield (on common stock)		-
	In January 2014 all of the option issued to the officers and directors were cancelled.
	In March 2014, we issued non-qualified options to purchase 2,916,000 shares of our common stock for services rendered to a director of the Company. The options have a term of 10 years, are exercisable at $0.0067 per share and vested when they were issued.
	The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $9,078. The options have been expensed equity based compensation. The following assumptions were used in the Black-Scholes option pricing model:
	Expected life (in years)		10
	Volatility (based on a comparable companies)		123	%
	Risk Free interest rate		2.73	%
	Dividend yield (on common stock)		-
	In May 2014, we issued non-qualified options to purchase 4,500,000 shares of our common stock to certain officers of the Company. The options are exercisable at $0.20 per share and have graded vesting over 4 years.
	The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $4,415,649. The options have been expensed equity based compensation. The following assumptions were used in the Black-Scholes option pricing model:
	Expected life (in years)		10
	Volatility (based on a comparable companies)		123	%
	Risk Free interest rate		2.56	%
	Dividend yield (on common stock)		-
	As per guidance in the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), we are amortizing the fair value of the options on a straight line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards (graded vesting attribution method).
	The following is a summary of outstanding stock options issued to employees and directors as of September 30, 2014:
		Number of			Exercise		Average					Aggregate
		Options			price		remaining					intrinsic value
					per share		term in years					at date of grant
	Outstanding September 30, 2013		-		$	-				-			$	-
	Issued		8,803,500		$	0.0067- 0.20			-						-
	Cancelled		1,387,500		$	0.0067			-						-
	Outstanding September 30, 2014		7,416,000		$	0.20			9.57			$			-
	Exercisable		3,166,000		$	0.0067			9.47			$			-
	The aggregate intrinsic value at September 30, 2014 is $1,535,500.  There was no intrinsic value at September 30, 2013.
	The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of September 30, 2014:
		Number of			Exercise		Average			Aggregate
		Options			price		remaining			intrinsic value
					per share		term in years			at date of grant
	Outstanding September 30, 2013		-		$	-		-		$	-
	Issued		375,000		$	0.0067
	Cancelled		-		$	-		-
	Outstanding September 30, 2014		375,000		$	0.0067		9.05		$	-
	Exercisable		-		$	-		-		$	-

Note_8_Income_Tax

Note 8 - Income Tax	12 Months Ended
	Sep. 30, 2014
Notes
Note 8 - Income Tax	Note 8 – Income Tax
	Income tax provision (benefit) for the years ended September 30, 2014 and 2013 is summarized below:
		2014			2013
	Current:
	Federal	$	-		$	-
	State		-			-
	Total current		-			-
	Deferred:
	Federal		(350,400	)		(4,200	)
	State		(31,500	)		(700	)
	Total deferred		(381,900	)		(4,900	)
	Increase in valuation allowance		381,900			4,900
	Total provision	$	-		$	-
	The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate before provision for income taxes. The sources and tax effect of the differences are as follows:
		2014			2013
	Income tax provision at the federal statutory rate		34	%		34	%
	State income taxes, net of federal benefit		3.3	%		5.8	%
	Effect of net operating loss		(37.3	%)		(39.8	%)
			-	%		-	%
	Components of the net deferred income tax assets at September 30, 2013 and 2012 were as follows:
		2014			2013
	Net operating loss carryover	$	381,900		$	34,100
	In March 2014 there was a significant change in control of the Company which resulted in a loss of NOL carryforwards available through that date.
	ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of evidence, it is more than likely than not that some portion or all of the deferred tax assets will not be recognized. After consideration of all the evidence, both positive and negative, management has determined that a $381,900 and $34,100 allowance at September 30, 2014 and 2013, respectively, is necessary to reduce the deferred tax assets to the amount that will more likely than not be realized. The change in the valuation allowance for the current year is $347,800.
	As of September 30, 2014, we have a net operating loss carry forward of approximately $1,030,500. The loss will be available to offset future taxable income. If not used, this carry forward will expire as follows in 2034.
	There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit our tax returns from 2011 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statement of operations. There have been no income tax related interest or penalties assessed or recorded.

Note_9_Subsequent_Events

Note 9 - Subsequent Events	12 Months Ended
	Sep. 30, 2014
Notes
Note 9 - Subsequent Events	Note 9 – Subsequent Events
	Subsequent to September 30, 2014, we were named as a defendant in a lawsuit relating to Canna-Pet LLC.  The suit claimed that the defendants have misappropriated trade secrets owned by the plaintiffs and are using them in the production and sale of Canna-Pet products.  We are named as a defendant in the litigation because we are the exclusive licensee with Canna-Pet, LLC.  Under the terms of our License Agreement, Canna-Pet, LLC, is obligated to indemnify and defend us in this litigation.  Canna-Pet, LLC, and it member, deny that they have misappropriated trade secrets from the plaintiffs.  On December 30, 2014, the parties to the law suit entered into a settlement agreement, and the case was dismissed.  There were no monetary damages to any party in the suit nor will the settlement affect our business in the future.
	In December 2014, we issued 200,000 restricted shares of our common stock to an investment banking firm, pursuant to an agreement to assist us in raising additional capital.  Although the agreement was executed on September 28, 2014, the contract was not approved by the investment banking firm’s investment committee until December 2014, at which time the shares were issued.  The value of the shares at the date of issuance will be included in subsequent financial statements.

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies: Basis of Consolidation (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Basis of Consolidation	Basis of Consolidation
	The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak Biopharma Inc. All inter-company balances and transactions among the companies have been eliminated upon consolidation.

Note_1_Summary_of_Significant_2

Note 1 - Summary of Significant Accounting Policies: Development Stage Company (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Development Stage Company	Development Stage Company
	The company has limited operations and is considered to be in the development stage. In the year ended September 30, 2014, the Company has elected to early adopt Financial Accounting Standards Board ("F ASB") Accounting Standards Update ("ASU") No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage.

Note_1_Summary_of_Significant_3

Note 1 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Use of Estimates	Use of Estimates
	The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues and expenses during the years reported. Actual results may differ from these estimates.

Note_1_Summary_of_Significant_4

Note 1 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Cash and Cash Equivalents	Cash and cash equivalents
	Our financial instruments consist of cash and cash equivalents, prepaid expenses, payables, and accrual. The carrying values of these instruments approximate fair value because of the short term maturities of these instruments.

Note_1_Summary_of_Significant_5

Note 1 - Summary of Significant Accounting Policies: Fair Value Measurements (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Fair Value Measurements:	Fair Value Measurements:
	ASC Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange.
	Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs.
	Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights.

Note_1_Summary_of_Significant_6

Note 1 - Summary of Significant Accounting Policies: Intangible and Long Lived Assets (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Intangible and Long Lived Assets	Intangible asset
	Intangible asset is our website and is being amortized over the expected useful lives which we estimate to be three.  Amortization expense charges to income for the year ended September 30, 2014 was $4,861.  There was no amortization expense for the year ended September 30, 2013.
	Long-lived assets
	On a periodic basis, management assesses whether there are any indicators that the value of our long-lived assets may be impaired. An asset’s value may be impaired only if management’s estimate of the aggregate future cash flows, on an undiscounted basis, to be generated by the asset are less than the carrying value of the asset.
	Our only longed lived asset is our website.  If impairment has occurred, the loss is measured as the excess of the carrying amount of the asset over its fair value.  Our estimates of aggregate future cash flows expected to be generated by our long-lived asset are based on a number of assumptions that are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in their impairment analyses may not be achieved. As of September 30, 2014, there was no asset impairment.

Note_1_Summary_of_Significant_7

Note 1 - Summary of Significant Accounting Policies: Research and Development (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Research and Development	Expenses associated with exploring business opportunities
	We were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of PWS Notes and other payments under the JV Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the assumption of debt related to the JV Agreement (See Note 4) and $2,413 which is the fair value of options granted to PWS (See Note 7).
	Research and Development
	Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $30,000 in research and development expenses for the year ended September 30, 2014.  There were no research and development expenses in 2013.

Note_1_Summary_of_Significant_8

Note 1 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Income Taxes	Income Taxes
	The provision for income taxes is determined in accordance with the provisions of ASC Topic 740, Accounting for Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements, uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
	For the years ended September 30, 2014 and 2013 we did not have any interest and penalties or any significant unrecognized uncertain tax positions. As of September 30, 2014 and 2013, we did not have any significant unrecognized uncertain tax positions.

Note_1_Summary_of_Significant_9

Note 1 - Summary of Significant Accounting Policies: Loss Per Share (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Loss Per Share	Loss per Share
	We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period, and diluted earnings per share is computed by including Common Stock equivalents outstanding for the period in the denominator. We have not issued any potentially dilutive common shares. At September 30, 2014 and 2013 any equivalents would have been anti-dilutive as we had losses for the periods then ended.

Recovered_Sheet1

Note 1 - Summary of Significant Accounting Policies: Recent Pronouncements (Policies)	12 Months Ended
	Sep. 30, 2014
Policies
Recent Pronouncements	Recent Pronouncements
	From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.  ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly.

Recovered_Sheet2

Note 1 - Summary of Significant Accounting Policies: Fair Value Measurements: Schedule of Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule of Fair Value Measurements	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange.
	Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs.
	Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights.

Note_2_Intangibles_Schedule_of

Note 2 - Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables)	12 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
	Years ending September 30,	Total Amortization
	2015	$	11,667
	2016		11,667
	2017		6,805
		$	30,139

Note_5_Commitments_and_Conting1

Note 5 - Commitments and Contingencies: Guaranteed Minimum Royalty Payments (Tables)	12 Months Ended
	Sep. 30, 2014
Tables/Schedules
Guaranteed Minimum Royalty Payments
	Time Period		Minimum Annual License Fee
	January 1, 2015 through December 31, 2015			-1
	January 1, 2016 through December 31, 2016			-2
	January 1, 2017 through December 31, 2017			-2
	January 1, 2018 through December 31, 2018			-2
	January 1, 2019 through December 31, 2019			-2
	January 1, 2020 through December 31, 2020, and all succeeding years			-3
	(1)	Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000.
	(2)	Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31.
	(3)	The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019.

Note_7_Options_Schedule_of_Sha

Note 7 - Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables)	12 Months Ended
	Sep. 30, 2014
Option One
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
	Expected life (in years)	10
	Volatility (based on a comparable companies)	130	%
	Risk Free interest rate	2.71	%
	Dividend yield (on common stock)	-
Option Two
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
	Expected life (in years)	10
	Volatility (based on a comparable companies)	130	%
	Risk Free interest rate	2.71	%
	Dividend yield (on common stock)	-
Option Three
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
	Expected life (in years)	10
	Volatility (based on a comparable companies)	123	%
	Risk Free interest rate	2.73	%
	Dividend yield (on common stock)	-
Option Four
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
	Expected life (in years)	10
	Volatility (based on a comparable companies)	123	%
	Risk Free interest rate	2.56	%
	Dividend yield (on common stock)	-

Note_7_Options_Schedule_of_Sha1

Note 7 - Options: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	12 Months Ended
	Sep. 30, 2014
Employee
Schedule of Share-based Compensation, Stock Options, Activity
		Number of		Exercise		Average					Aggregate
		Options		price		remaining					intrinsic value
				per share		term in years					at date of grant
	Outstanding September 30, 2013		-	$	-				-			$	-
	Issued		8,803,500	$	0.0067- 0.20			-						-
	Cancelled		1,387,500	$	0.0067			-						-
	Outstanding September 30, 2014		7,416,000	$	0.20			9.57			$			-
	Exercisable		3,166,000	$	0.0067			9.47			$			-
Non-Employee
Schedule of Share-based Compensation, Stock Options, Activity
		Number of		Exercise		Average			Aggregate
		Options		price		remaining			intrinsic value
				per share		term in years			at date of grant
	Outstanding September 30, 2013		-	$	-		-		$	-
	Issued		375,000	$	0.0067
	Cancelled		-	$	-		-
	Outstanding September 30, 2014		375,000	$	0.0067		9.05		$	-
	Exercisable		-	$	-		-		$	-

Note_8_Income_Tax_Schedule_of_

Note 8 - Income Tax: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)
		2014			2013
	Current:
	Federal	$	-		$	-
	State		-			-
	Total current		-			-
	Deferred:
	Federal		(350,400	)		(4,200	)
	State		(31,500	)		(700	)
	Total deferred		(381,900	)		(4,900	)
	Increase in valuation allowance		381,900			4,900
	Total provision	$	-		$	-

Note_8_Income_Tax_Schedule_of_1

Note 8 - Income Tax: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Sep. 30, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
		2014		2013
	Net operating loss carryover	$	381,900	$	34,100

Recovered_Sheet3

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Details
Accumulated Deficit	($3,859,055)	($100,240)

Note_2_Intangibles_Details

Note 2 - Intangibles (Details) (USD $)	12 Months Ended
	Sep. 30, 2014
Details
Website Development Cost	($35,000)
Amortization of Website	$4,861

Note_2_Intangibles_Schedule_of1

Note 2 - Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) (USD $)	Sep. 30, 2014
Details
Estimated Future Amortization Expense 2015	$11,667
Estimated Future Amortization Expense 2016	11,667
Estimated Future Amortization Expense 2017	6,805
Intangible Asset, Net of Amortization	$30,139

Note_3_Related_Party_Transacti1

Note 3 - Related Party Transactions (Details) (USD $)	12 Months Ended
	Sep. 30, 2014
Details
Stock Issued During Period, Shares, Other	1,479,000
Due to Officers or Stockholders, Current	$34,510
Fair Value of Shares	9,860
Fair Value Assumptions, Exercise Price	$0.01
Gain on Conversion of Debt	($24,650)

Note_4_ShortTerm_Convertible_N1

Note 4 - Short-Term Convertible Notes Payable (Details) (USD $)	9 Months Ended	12 Months Ended
	Jun. 30, 2014	Sep. 30, 2014
Details
Short-term Debt, Lender		PWS and Montrose Capital Limited
Short-term Debt		$602,932
Conversion Price	0.2
Debt Conversion, Original Debt, Amount	602,932
Debt Instrument, Increase, Accrued Interest	46,848
Shares Issued for Debt Conversion (shares)	3,248,898
Interest Expense, Debt		$649,780

Note_5_Commitments_and_Conting2

Note 5 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Sep. 30, 2014
Details
Operating Leases, Future Minimum Payments Due	$13,750
Operating Leases, Rent Expense, Net	$4,667

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2014
Stock Issued During Period, Shares, Other			1,479,000
Due to Officers or Stockholders, Current			$34,510
Equity Based Compensation			1,222,357
Shares Issued for Services to Employees and Non-Employees			787,759
Restricted Shares of Common Stock (shares)	200,000
Shares Issued for Debt Conversion (shares)		3,248,898
10-Oct-13
Shares Issued			30,000,000
Shares Issued, Price Per Share			$0.01
Proceeds from Issuance of Common Stock			200,000
Shares Cancelled (Shares)			300,000,000
11-Mar-14
Shares Issued, Price Per Share			$0.01
Shares Repurchased (Shares)			29,500,000
Shares Repurchased			100,000
Stock Issued For Services			37,584,000
Equity Based Compensation			250,599
15-Oct-13
Shares Issued			3,750,000
Shares Issued, Price Per Share			$0.01
Proceeds from Issuance of Common Stock			25,000
30-Jan-14
Shares Repurchased (Shares)			3,750,000
Shares Repurchased			25,000
15-Nov-13
Stock Issued During Period, Shares, Other			1,479,000
Due to Officers or Stockholders, Current			34,510
April through September 2014
Shares Issued			4,075,000
Shares Issued, Price Per Share			$0.20
Proceeds from Issuance of Common Stock			815,000
15-May-14
Shares Issued, Price Per Share			$1.02
Stock Issued For Services			466,666
Shares Issued for Services to Employees and Non-Employees			476,000
25-Jun-14
Shares Issued, Price Per Share			$1.02
Restricted Shares of Common Stock (shares)			60,000
Restricted Shares of Common Stock			$61,200
30-Jun-14
Shares Issued for Debt Conversion (shares)			3,248,898

Note_7_Options_Schedule_of_Sha2

Note 7 - Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Sep. 30, 2014
Option One
Expected Life	10 years
Volatility	130.00%
Risk Free Interest Rate	2.71%
Option Two
Expected Life	10 years
Volatility	130.00%
Risk Free Interest Rate	2.71%
Option Three
Expected Life	10 years
Volatility	123.00%
Risk Free Interest Rate	2.73%
Option Four
Expected Life	10 years
Volatility	123.00%
Risk Free Interest Rate	2.56%

Note_7_Options_Schedule_of_Sha3

Note 7 - Options: Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $)	12 Months Ended
	Sep. 30, 2014
Employee
Options Outstanding	7,416,000
Exercise Price	$0.20
Average Remaining Term in Years - Options Outstanding	9 years 6 months 25 days
Options Issued	8,803,500
Exercise Price - Options Issued Lower Range	$0.01
Exercise Price - Options Issued Upper Range	$0.20
Options Cancelled	1,387,500
Exercise Price - Options Cancelled	$0.01
Options Exercisable	3,166,000
Exercise Price - Options Exercisable	$0.01
Remaining Term in Years - Options Exercisable	9 years 5 months 19 days
Non-Employee
Options Outstanding	375,000
Exercise Price	$0.01
Average Remaining Term in Years - Options Outstanding	9 years 18 days
Options Issued	375,000
Exercise Price - Options Issued Upper Range	$0.01

Note_8_Income_Tax_Schedule_of_2

Note 8 - Income Tax: Schedule of Components of Income Tax Expense (Benefit) (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Details
Deferred Federal Income Tax Expense (Benefit)	($350,400)	($4,200)
Deferred State and Local Income Tax Expense (Benefit)	-31,500	-700
Deferred Income Tax Expense (Benefit)	-381,900	-4,900
Change in Valuation Allowance	$381,900	$4,900

Note_8_Income_Tax_Details

Note 8 - Income Tax (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Details
Income Tax Provision at the Federal Statutory Rate	34.00%	34.00%
State Income Taxes, Net of Federal Benefit	3.30%	5.80%
Effective Income Tax Rate Reconciliation, Percent	-37.30%	-39.80%
Valuation Allowance	$381,900	$34,100
Change in Valuation Allowance	347,800
Operating Loss Carryforwards	$1,030,500

Note_8_Income_Tax_Schedule_of_3

Note 8 - Income Tax: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Details
Deferred Tax Assets, Operating Loss Carryforwards	$381,900	$34,100

Note_9_Subsequent_Events_Detai

Note 9 - Subsequent Events (Details)	3 Months Ended
	Dec. 31, 2014
Details
Restricted Shares of Common Stock (shares)	200,000